Last reviewed · How we verify
Erythropoietin subcutaneously and Iron intravenously
Erythropoietin subcutaneously and Iron intravenously is a Erythropoiesis-stimulating agent combined with iron supplement Small molecule drug developed by Catharina Ziekenhuis Eindhoven. It is currently FDA-approved for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Iron deficiency anemia. Also known as: Eprex, Ferinject.
Erythropoietin stimulates red blood cell production while intravenous iron provides the essential substrate for hemoglobin synthesis.
Erythropoietin stimulates red blood cell production while intravenous iron provides the essential substrate for hemoglobin synthesis. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Iron deficiency anemia.
At a glance
| Generic name | Erythropoietin subcutaneously and Iron intravenously |
|---|---|
| Also known as | Eprex, Ferinject |
| Sponsor | Catharina Ziekenhuis Eindhoven |
| Drug class | Erythropoiesis-stimulating agent combined with iron supplement |
| Target | Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Erythropoietin (EPO) is a cytokine that binds to erythropoietin receptors on bone marrow progenitor cells, promoting their differentiation and proliferation into mature red blood cells. Iron supplementation ensures adequate iron availability for hemoglobin synthesis, as iron is a critical component of the heme molecule. Together, these agents address both the signaling deficiency and nutritional substrate needed for effective erythropoiesis.
Approved indications
- Anemia of chronic kidney disease
- Chemotherapy-induced anemia
- Iron deficiency anemia
Common side effects
- Hypertension
- Thrombosis
- Headache
- Injection site reactions
- Gastrointestinal disturbance (iron-related)
Key clinical trials
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) (PHASE3)
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) (PHASE3)
- Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery (PHASE4)
- Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA) (NA)
- Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erythropoietin subcutaneously and Iron intravenously CI brief — competitive landscape report
- Erythropoietin subcutaneously and Iron intravenously updates RSS · CI watch RSS
- Catharina Ziekenhuis Eindhoven portfolio CI
Frequently asked questions about Erythropoietin subcutaneously and Iron intravenously
What is Erythropoietin subcutaneously and Iron intravenously?
How does Erythropoietin subcutaneously and Iron intravenously work?
What is Erythropoietin subcutaneously and Iron intravenously used for?
Who makes Erythropoietin subcutaneously and Iron intravenously?
Is Erythropoietin subcutaneously and Iron intravenously also known as anything else?
What drug class is Erythropoietin subcutaneously and Iron intravenously in?
What development phase is Erythropoietin subcutaneously and Iron intravenously in?
What are the side effects of Erythropoietin subcutaneously and Iron intravenously?
What does Erythropoietin subcutaneously and Iron intravenously target?
Related
- Drug class: All Erythropoiesis-stimulating agent combined with iron supplement drugs
- Target: All drugs targeting Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
- Manufacturer: Catharina Ziekenhuis Eindhoven — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia of chronic kidney disease
- Indication: Drugs for Chemotherapy-induced anemia
- Indication: Drugs for Iron deficiency anemia
- Also known as: Eprex, Ferinject
- Compare: Erythropoietin subcutaneously and Iron intravenously vs similar drugs
- Pricing: Erythropoietin subcutaneously and Iron intravenously cost, discount & access